SEC Tracker
Get the app
MDXG · XBRL financial data

Mimedx Group financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (MDXG's year ends in late December)

In thousands of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Revenue from contracts with customers86,832*84,70987,20784,05792,907*88,20598,605113,725118,095*58,99164,36262,283
Cost of goods and services sold13,842*12,98714,85515,32216,909*16,55818,68118,71919,055*17,36819,98112,581
Gross profit72,990*71,72272,35268,73575,998*71,64779,92495,00699,040*41,62344,38149,702
Research and development(5,503)*2,8413,0122,9183,571*3,3283,3033,7034,761*4,1402,7772,796
Selling, general and administrative54,351*55,12955,40153,51661,043*59,96964,15169,00173,073*53,23159,77958,313
General and administrativeyear only10,65213,67611,79513,403*13,10816,28415,28111,840*9,319——
Operating income (loss)26,890*13,19823,45011,16211,054*8,25112,37022,19021,077*(16,049)(18,466)(11,702)
Interest incomeyear only684525799924*9841,2131,2101,309*1,288——
Interest expenseyear only2,374522521521*478475425405*402——
Other income (expense)16*(99)(237)(21)(208)*(145)(101)(126)(186)*(168)(102)(136)
Income tax expense (benefit)(37,375)*2,3485,5953,5413,811*1,5893,3896,1016,604*(4,471)(2,940)(2,379)
Net income (loss)53,477*9,26117,6258,0957,438*7,0239,61816,74815,191*(10,860)(14,840)(8,683)
Earnings per share, basic USD per share0.45*0.060.120.050.05*0.050.070.110.10*(0.07)(0.10)(0.06)
Earnings per share, diluted USD per share—0.060.120.050.05*0.050.060.110.10*(0.07)(0.10)(0.06)
Weighted average shares, basic thousands of shares119,367*146,405147,326146,959147,225*147,272147,761148,035148,092*148,446147,796145,865
Weighted average shares, diluted thousands of shares—150,028148,898148,374148,906*149,677149,317149,714150,184*148,446147,796145,865

Balance sheet

CSV

Fiscal quarters (MDXG's year ends in late December)

In thousands of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Cash and cash equivalents82,00048,48769,03788,801104,416106,431118,869142,083166,121159,773135,839120,791
Accounts receivable53,87157,01652,79854,03055,82862,28869,22878,18675,70746,03441,29737,269
Inventory21,02124,45425,05624,24923,80724,07024,89026,50225,34026,22820,93122,088
Total current assets164,261138,853154,018172,139191,886200,112220,876254,095277,471240,326205,365187,233
Right-of-use asset2,1323,4993,1752,8435,6065,2994,9874,6684,344———
Goodwill19,44119,44119,44119,44119,44119,44119,44119,44119,44119,44119,44119,441
Total assets239,047221,681230,183243,891263,915270,420291,109318,988342,653308,676280,998264,552
Accounts payable9,0489,6977,6036,9247,4098,8688,49911,41514,52811,4648,29311,828
Accrued liabilities9,3619,1969,2818,3969,0129,44715,10512,82511,38311,00811,14012,768
Current portion of long-term debt1,0001,0001,0001,0001,0001,1251,2501,3751,5001,5001,5000
Total current liabilities46,00842,22140,01241,94145,59542,61950,29057,68264,26644,55038,49843,031
Long-term debt48,09918,45318,24918,01817,83017,53317,21116,83916,46716,09415,7060
Lease liability, non-current893———4,705———3,245———
Total liabilities96,33065,95062,14362,88370,80867,64474,48580,04286,10565,74064,99553,470
Accumulated deficit(133,678)(124,417)(106,792)(98,697)(91,259)(84,236)(74,620)(57,872)(42,681)(53,541)(68,381)(77,064)
Total stockholders' equity142,717155,731168,040181,008193,107202,776216,624238,946256,548242,936216,003211,082
Total liabilities and equity239,047221,681230,183243,891263,915270,420291,109318,988342,653308,676280,998264,552
Common shares outstanding (cover page) thousands of shares146,958147,604146,809146,946147,366147,702147,959148,102148,567148,946145,760145,926

Cash flows

CSV

Fiscal quarters (MDXG's year ends in late December)

In thousands of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Net income (loss)53,477*9,26117,6258,0957,438*7,0239,61816,74815,191*(10,860)(14,840)(8,683)
Stock-based compensation4,166*4,3404,091*3,809*4,693*4,2624,752*4,919*2,463*(1,696)903*3,212*
Depreciation and amortizationyear only———year only———year only———
Net cash from operating activities10,257*5,97821,814*19,624*18,782*5,29914,419*29,329*24,956*1,879(10,015)*3,919*
Purchases of property and equipment427*———————————
Net cash from investing activities(481)*(6,024)(905)*113*(2,767)*(406)(887)*(5,258)*(335)*(5,642)(635)*(193)*
Share repurchasesyear only———year only——0*0*——304*
Net cash from financing activities(8,940)*(33,467)(359)*27*(400)*(2,878)(1,094)*(857)*(583)*(2,585)(13,284)*(18,774)*
Net change in cash836*(33,513)20,550*19,764*15,615*2,01512,438*23,214*24,038*(6,348)(23,934)*(15,048)*

Compare with peers

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Mimedx Group120,79162,2833,919*145.9M— 10-QSep 30, 2026
Embecta214,700271,70041,800*56.7M— 10-QJun 30, 2026
Heartflow34,36264,082(8,577)*87.0M19.0 quarters 10-QJun 30, 2026
SI-BONE35,31155,7045,940*45.1M— 10-QSep 30, 2026
Beta Bionics81,55135,505(12,287)*54.4M13.0 quarters 10-QSep 30, 2026
Kestra Medical Technologies68,55830,971(32,295)59.6M4.9 quarters 10-QJul 31, 2026
Biolife Solutions23,997not reported6,348*48.9M— 10-QJun 30, 2026
Cadre Holdings53,984207,12622,131*42.8M— 10-QJun 30, 2026
Avanos Medical65,600182,200(12,300)46.8M5.3 quarters 10-QMar 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.